Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hung Cheng-Hsien, Yen Fu-Shun, Huang Jing-Yang, Cheng-Chung Wei James
Аннотация
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus (T2DM). The long-term impact on cancer risk remains uncertain. This study aimed to evaluate the association between GLP-1 RA and the risk of cancer, including site-specific malignancies.
METHODS: This retrospective cohort study utilized the TriNetX database. Adults with T2DM between 2015 and 2023 were identified. After 1:1 propensity score matching, 144 410 GLP-1 RA users were compared with nonusers. Primary outcomes were all-cause mortality and incident malignant neoplasms. Secondary outcomes included site-specific cancers.
RESULTS: GLP-1 RA use was associated with lower all-cause mortality (hazard ratio [HR] 0.693) and a reduced overall incidence of cancer (HR 0.905). Regarding nonendocrine malignancies, significant risk reductions were observed for digestive cancers (HR 0.710) and respiratory cancers (HR 0.691), as well as for other sites including oral, female genital, and central nervous system cancers. In contrast, GLP-1 RA was linked to an increased risk of thyroid gland cancer (HR 1.411). Active-comparator analyses against dipeptidyl peptidase-4 inhibitor and sodium-glucose co-transporter 2 inhibitor yielded broadly consistent findings. Landmark analyses at 3 years showed attenuation of the thyroid cancer signal to nonsignificance, suggesting surveillance bias rather than a true carcinogenic effect.
CONCLUSION: This real-world analysis demonstrates divergent oncologic risks associated with GLP-1 RA use, while the therapy offers potential protective effects against nonendocrine malignancies (particularly digestive and respiratory). The initially elevated thyroid cancer risk was no longer significant at 3 years, suggesting surveillance bias. These findings support the overall oncologic safety of GLP-1 RA in T2DM management, while warranting further long-term studies to confirm these associations.
METHODS: This retrospective cohort study utilized the TriNetX database. Adults with T2DM between 2015 and 2023 were identified. After 1:1 propensity score matching, 144 410 GLP-1 RA users were compared with nonusers. Primary outcomes were all-cause mortality and incident malignant neoplasms. Secondary outcomes included site-specific cancers.
RESULTS: GLP-1 RA use was associated with lower all-cause mortality (hazard ratio [HR] 0.693) and a reduced overall incidence of cancer (HR 0.905). Regarding nonendocrine malignancies, significant risk reductions were observed for digestive cancers (HR 0.710) and respiratory cancers (HR 0.691), as well as for other sites including oral, female genital, and central nervous system cancers. In contrast, GLP-1 RA was linked to an increased risk of thyroid gland cancer (HR 1.411). Active-comparator analyses against dipeptidyl peptidase-4 inhibitor and sodium-glucose co-transporter 2 inhibitor yielded broadly consistent findings. Landmark analyses at 3 years showed attenuation of the thyroid cancer signal to nonsignificance, suggesting surveillance bias rather than a true carcinogenic effect.
CONCLUSION: This real-world analysis demonstrates divergent oncologic risks associated with GLP-1 RA use, while the therapy offers potential protective effects against nonendocrine malignancies (particularly digestive and respiratory). The initially elevated thyroid cancer risk was no longer significant at 3 years, suggesting surveillance bias. These findings support the overall oncologic safety of GLP-1 RA in T2DM management, while warranting further long-term studies to confirm these associations.